Vol. 90, Issue 5, 1977-1985, May 2001
INNOVATIVE TECHNIQUES
Method for measuring long-term function of muscle-powered
implants via radiotelemetry
Dennis R.
Trumble and
James A.
Magovern
Cardiothoracic Surgery Research, Allegheny-Singer Research
Institute, and Department of Surgery, Allegheny General Hospital, West
Penn Allegheny Health System, Pittsburgh, Pennsylvania 15212
 |
ABSTRACT |
Long-term remote monitoring of muscle-powered
implants has been made possible with development of an adjustable
workload that can be remotely monitored to assess device function. This
technique obviates the need for percutaneous access lines and allows
test animals to remain untethered, eliminating deleterious effects caused by infection, sedation, or animal stress. Hardware components include a latex bladder fixed within a hermetically sealed canister, multichannel implantable telemetry unit, and subcutaneous access port
(for pressure charge adjustment). To validate this method, in vitro
tests were performed by using a third-generation muscle energy
converter designed to function as an implantable hydraulic pump.
Two channels of telemetered pressure data were collected and used to
calculate six indexes of device function. Calculated parameters were then compared with measured values to
determine accuracy. Correlation between measured and calculated
parameters was high in all instances, with most estimates yielding
errors of <3%. These results demonstrate the utility of this approach and support its use as a means to monitor muscle-powered devices during
long-term animal trials.
motor prostheses; latissimus dorsi; muscle energy
converter; blood pump
 |
INTRODUCTION |
THE POTENTIAL HEALTH
BENEFITS to be gained by harnessing skeletal muscle power for
circulatory support are substantial. Successfully tapping this
autologous energy source would breach an important barrier that has
prevented current blood pump technology from becoming a viable,
cost-effective means to treat congestive heart failure, which is a
devastating disease that continues to increase in prevalence in our
society despite the aggressive application of advanced pharmacological
therapies (5). The availability of a practical muscle
energy transmission scheme would breathe new life into the field of
mechanical cardiac support, providing a means to develop self-contained
systems fueled by the same metabolic processes that drive the heart
itself. Hybrid implants of this sort would provide a much-needed
alternative to cardiac transplantation without the limitations of donor
availability, the complications of coronary artery vasculopathy, and
the expense of immunosuppressive drugs.
Progress toward developing a practical prosthesis to harvest muscle
power has been slowed, however, because of complexities of device
design and difficulties associated with monitoring long-term device
function in vivo. System durability and energy transfer efficiency have
proven to be key design considerations from a mechanical perspective,
and important refinements in device architecture have been realized in
recent years. Still, fundamental questions regarding device
biocompatibility (14) and steady-state work capacity
(12) have remained largely unanswered for lack of a simple, reliable means to assess system performance under chronic implant conditions.
Long-term monitoring of motor implants has now been made possible with
development of a subcutaneous muscle-actuated accumulator and
radiotelemetry (SMART) system designed to provide both regulated pressure loads and a means to measure device and muscle function via
remote sensing. Through this mechanism, device loading can be
easily adjusted and performance data collected at any time without the
need for sedation or general anesthesia, which may influence
contractile function. Moreover, this system obviates the need for
percutaneous access lines and allows test animals to remain untethered,
thereby eliminating deleterious effects caused by infection and animal
stress. As a result, long-term studies of in vivo device performance,
steady-state muscle function, and tissue response to device
implantation can now be performed by using this novel test system.
This report outlines the fundamental principles of SMART system
operation and describes individual hardware components, data transmission techniques, and results from preliminary in vitro testing.
Recent improvements in muscle energy converter (MEC) design and
functional parameters are also described.
 |
MEC DESIGN AND OPERATION |
The most salient aspects of MEC design and function have not
changed appreciably since they were first described in 1997 (13). In brief, this device assumes the form of a
cylindrical pump, 12-14 cm in length, with a reciprocating piston
stationed at one end. The MEC is positioned beneath the humeral
insertion of the latissimus dorsi (LD) muscle so that the tendon can be
attached to the piston head and the muscle used to actuate the pump. LD contractions are governed by an implanted stimulator that sends short
bursts of electrical impulses to the thoracodorsal nerve. Contractile
energy is transferred to the transmission medium (water or silicone
oil) via an internal metal bellows that serves as a low-friction piston
seal. The entire mechanism is mounted to the chest wall by using a
perforated titanium backing plate to provide a stable anchor point for
pump operation.
Extensive in vitro testing of earlier prototype devices has yielded an
improved third-generation muscle pump (MEC3) capable of delivering
contractile energy at rates exceeding 340 mJ per actuation cycle (Fig.
1). Device modifications were implemented to improve power transfer capacity beyond that of the original MEC
prototype (135 mJ/stroke) while reducing the relatively high muscle
force requirements imposed by the second-generation device (owing to
high bellows spring rates). Current MEC3 configuration and component
parts are illustrated in Fig. 2. Details
regarding device form and function are summarized below.

View larger version (117K):
[in this window]
[in a new window]
|
Fig. 1.
Third-generation muscle energy converter (MEC3) shown
with tendon and chest wall anchoring schemes. Muscle attachment
involves inserting the latissimus dorsi tendon into a toothed clamp
stationed at the end of the piston (top). Chest wall
fixation is achieved via a perforated metal backing plate designed to
promote fibrous tissue ingrowth.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 2.
Scale drawing of MEC3 implant shown in cross section to
illustrate pump architecture. Device components include piston head
(A), muscle tendon clamp (B), graft sheathing
(C), low-friction sleeve bearings (D), upper
housing (E), piston shaft with stroke-limiting step
(F), vent holes for volume compensation between bellows and
graft sheathing (G), stainless steel bellows seal (H),
and lower housing (I).
|
|
The MEC3 features a low-pressure stainless steel bellows seal with an
effective pressure area of 3.16 cm2, a nominal spring rate
of 4.4 N/cm, and a volumetric compliance of 9.67 × 10
3 cm3/kPa. The bellows is heat treated to
cycle in compression for maximum durability, and, as a result, resting
fluid pressures of ~40 kPa are needed to both extend the piston and
preload the muscle. Bellows integrity is further safeguarded by
limiting piston stroke lengths to
16 mm. The outer bellows seal used
in previous designs has been replaced with a length of reinforced
expanded polytetrofluoroethylene graft (18 mm) that prevents body
fluids from contacting the bearing surface. Elimination of the
outer bellows minimizes overall device length and reduces MEC3 spring rate by an additional 50% beyond the low value already afforded by the
lighter inner bellows. Moreover, MEC3 spring rates now assist LD
shortening rather than working against the muscle as in prior designs.
The central shaft of the MEC3 is supported by two sleeve bearings lined
with FrelonGOLD, a low-friction, Teflon-based compound manufactured by
Pacific Bearing (Rockford, IL). Two bearings placed end to end
are required to prevent piston binding due to the cantilevered load
generated by the muscle. Internal volume compensation is achieved via
circular vents machined into the hollow central shaft. The lower
portion of the shaft is stepped to a slightly larger diameter to
provide a stop mechanism that limits the bellows compressed length,
thereby protecting the welded surfaces from wear due to impact stresses.
 |
TECHNIQUE FOR REMOTE MONITORING OF MEC FUNCTION |
As detailed in a previous report (14), MEC loading
conditions can be regulated in vivo using a subcutaneous
muscle-actuated accumulator (SMA). This device, adapted from an
implantable mock circulation system developed by Acker et al. (1,
2), comprises a latex bladder fixed within a hermetically sealed
titanium canister (Fig. 3). The bladder
insert receives fluid pumped from the MEC via a noncompliant conduit;
pressure loads are altered by simply injecting or removing air through
a vascular access port connected to the canister. Both fluid and gas
compartments are equipped with luer lock fittings for pressure
measurement purposes.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Subcutaneous muscle-actuated accumulator shown with luer lock
fittings for fluid (left) and gas (right) chamber
access. A thin metal rod is used to prevent longitudinal collapse of
the latex bladder, allowing preload and afterload pressures to be set
independently. Inset: the bladder fully inflated
(top) and completely evacuated (bottom) in both
longitudinal and axial views. Total device length = 14 cm;
external housing diameter = 2 cm.
|
|
By using this loading scheme, it becomes possible to calculate every
key MEC performance parameter on the basis of accumulator pressure
readings alone, including actuation force, stroke length, contraction
time, piston velocity, stroke volume, and energy output. This
information is computed by combining pressure readings with known
system constants such as bellows properties (e.g., effective area,
spring rate, and compliance) and resting canister air volume, a
parameter used to determine fluid volume displacement via Boyle's law.
Despite the relative simplicity of this approach, however, there
remains the need to insert a small-gauge needle though both skin and
access port septum to measure accumulator pressures. Percutaneous
access thus limits data collection to relatively brief time periods
during which the animal must be either restrained or sedated. Thus it
is important that a means be developed to monitor these waveforms
noninvasively, without having to disturb the animal under study.
To this end, a fully implantable radiotelemetry system (Data Sciences
International, St. Paul, MN) has been developed specifically for use
with the SMA. The housing of this device resembles a cardiac pacemaker
and comprises a silicone elastomere capsule that contains a battery,
two pressure sensors, and an electronics module (Fig. 4). A pair of fluid-filled catheters,
each capped with luer lock fittings, transmit device pressures to
solid-state transducers modified to accommodate the supraphysiological
pressures generated during MEC actuation. A proprietary
silicone-oil-like fluid is used as the transmission medium within the
catheter to improve frequency response and effect minimal diffusion
losses for a long working life (>2 yr). For this application, standard
amplifier gains are reduced to increase peak measurement capacity
roughly fivefold to 1,550 mmHg. Atmospheric pressure is monitored
continuously via an ambient pressure reference (model APR-1, Data
Sciences International) and added to telemetered gauge pressure
readings to yield absolute pressure data needed for stroke volume
calculations. Biopotential leads sheathed in silicone are used to
monitor muscle activity and provide temporal data relating LD
activation and energy transfer times. The electronics module converts
these analog readings to frequency-modulated digital signals and
transmits them as a series of pulses to a nearby receiver hardwired to
a computerized data-acquisition system. Data from each channel are transmitted at a rate of 400 Hz. Transmitter power may be cycled on and
off via a magnetically activated switch to extend battery life in
studies in which only intermittent monitoring is needed. Estimated
battery life under conditions of continuous use is 4 mo.

View larger version (133K):
[in this window]
[in a new window]
|
Fig. 4.
Implantable telemetry unit fitted with 2 fluid-filled catheters for accumulator pressure measurement
(top) and a pair of biopotential leads for recording muscle
activity (coiled at bottom). The implant body measures 5.5 cm in diameter and is 1.4 cm thick. Manufactured by Data Sciences
International (St. Paul, MN).
|
|
The integration of this remote sensing scheme with SMA technology has
yielded a totally implantable, self-contained system for chronic
testing of muscle-powered devices (Fig.
5). The principal advantage of this
approach is that it allows device function to be readily (and
continuously) monitored in conscious, untethered animals, thereby
avoiding the potential impact of sedation, anesthesia, or stress on
muscle performance. Moreover, the SMART system eliminates the risk of
percutaneous access line infection and thus can potentially be used to
test long-term implant function for periods of months or even years. In
fact, this technique requires only that the test animal be handled
during those brief periods when air is injected or withdrawn from the
accumulator to adjust loading conditions (note: a second subcutaneous
access port can be added should preload adjustments be required). At
all other times, device performance may be monitored without the need
for any direct contact with the animal under study.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Scale drawing of subcutaneous muscle-actuated accumulator
and radiotelemetry (SMART) system and MEC3 pump showing anatomic fit
within a 30- to 35-kg dog (latissimus dorsi muscle and burst stimulator
omitted for clarity). This system can also be used in pig, sheep, goat,
and calf models.
|
|
 |
DEVICE TESTING: MATERIALS AND METHODS |
The MEC-SMART complex was tested in vitro to assess both
muscle pump function and the accuracy of telemetric monitoring before live animal implantation. Muscle contractions were simulated
via a programmable linear actuator (SmartActuator, Ultramotion)
attached to a reciprocating rod guided by a Teflon bushing. The
actuator arm was attached to the MEC3 via a light metal chain
terminated by a 2 cm length of braided artificial tendon
(8) to simulate in vivo fixation conditions and allow the
piston to extend under its own power (the chain becoming slack during
rapid extension of the actuator arm to mimic low tension during LD
relaxation). The hydraulic output generated by these "contractions"
was pumped into the SMART system to 1) test the accuracy of
device performance calculations based on telemetry pressure readings
and 2) provide a controlled pressure load for MEC3 bench
testing. A miniature load cell (model ELH-TC401, Entran Devices) was
mounted between the drive rod and MEC3 to measure forces applied to the
muscle interface. Piston motion was monitored with a low-friction
linear potentiometer (model LP804-01, Omega Engineering) attached to the piston head. An in-line flow probe (model 8N, Transonic) was inserted into the pressure tubing and used to quantify fluid volume displacement. Force, displacement, and flow waveforms were digitized at
a rate of 500 samples/s and saved to a Compaq Armada E700 laptop computer using another data-acquisition package (DI-720-P DAS with
WinDaq/Pro+, Dataq Instruments).
To simulate in vivo measurement conditions, gas and fluid
pressures were measured by using an implantable telemetry unit (model TL11M3-D70-PCP) and saved to a Dataquest A.R.T. data-acquisition system
(Data Sciences International). Waveforms were collected simultaneously on both data-acquisition systems with the actuator cycled off-on-off and system clocks synchronized to produce event and
time markers common to both data sets. These data were then postprocessed by using XANALYZE, a comprehensive cardiovascular waveform analysis program developed at the National Institutes of
Health (11).
Calculations of device stroke volume, stroke work, stroke length,
contraction time, actuation speed, and muscle force based on
telemetered pressure measurements alone were compared with values
obtained via direct measurement over a wide range of resting gas
(afterload) pressures (50, 100, 150, and 200 kPa) and peak "contraction" speeds (10-100 mm/s; increments of 10), with the duration of actuation set at 250 ms and actuator stroke length limited
to 16 mm. Resting fluid pressure (preload) was fixed at 38.7 kPa to
rapidly extend the piston between actuation cycles, plus provide an
additional 5-N force at full extension (to overcome anticipated LD
resting tension and pressure from surrounding tissues). Once the system
was primed with fluid, a complete battery of 40 tests was performed
over a period of several days. Static pressure tests were also
performed over longer periods (up to 2 wk) to detect leakage of fluid
or gas from the system. These data were then used to 1)
quantify the accuracy of this telemetric monitoring technique,
2) calculate MEC3 energy transfer capacity at various afterload pressure settings, and 3) determine whether
system leakage rates are compatible with extended in vivo use.
Data analysis and statistical methods.
All summary data are expressed as means ± SD. Linear
regression analyses were performed by using the Marquardt-Levenberg
algorithm for iterative, least squares estimation of curve-fit parameters.
 |
RESULTS |
Typical force, displacement, and flow waveforms measured during
device testing are shown in Fig. 6 along
with corresponding gas and fluid pressure readings recorded via
radiotelemetry. No fluid leakage was detected during the course of
system testing, and gas pressures were found to be stable under both
static and dynamic operating conditions. As anticipated, fluid pressure
tracings were seen to change in proportion to actuation force over a
broad range of shortening speeds and stroke lengths. Similarly, gas pressure waveforms were found to closely follow changes in volumetric flow for stroke lengths ranging from 2.7 to 15.0 mm. These observations are consistent with the fundamental premise that accumulator pressure readings alone contain sufficient information to calculate key pump
performance parameters.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Simultaneous recordings of actuation force, piston displacement,
fluid flow, and accumulator pressures acquired during MEC3-SMART system
bench testing. Telemetered pressure readings (bottom) were
used to calculate 6 key muscle pump performance parameters. These
calculations were then compared with measured values to test the
accuracy of this monitoring technique.
|
|
The accuracy of MEC performance parameters computed from SMART pressure
readings is shown graphically in Fig. 7,
in which calculated values are plotted against those obtained via
direct measurement. SMART system measurement errors are further
delineated in Fig. 8 by using a method
described by Bland and Altman (3) in which differences
between estimated and measured values are plotted against their true
value. Estimates of peak actuation forces ranged from 12.5 to 73.6 N
and were in substantial agreement with measured values, differing by an
average of
5.0 ± 3.2 N (10.9 ± 6.5%). Contraction times,
defined as the period from initial force development to peak piston
displacement, were calculated at 0.247 to 0.310 s on the basis of the
time course of fluid pressure fluctuations. Absolute differences
between calculated and measured times averaged 0.005 ± 0.008 s.
Relative differences averaged 2.2%.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 7.
Linear regression plots showing correlation between calculated and
measured values of 6 key muscle pump performance parameters. Rsqr,
r2. A: peak actuation force.
B: contraction duration. C: stroke volume.
D: stroke length. E: mean (Mn) piston velocity
during actuation. F: stroke work output.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 8.
Graphs showing difference between calculated (Calc) and measured
(Meas) values plotted against their mean for 6 key muscle pump
performance parameters. Horizontal lines define mean difference and
95% confidence intervals. Avg, average. A: peak actuation
force (F). B: contraction duration (CT). C:
stroke volume (SV). D: stroke length (SL). E:
mean piston velocity during actuation (PV). F: stroke work
output (SW).
|
|
Device performance parameters calculated from accumulator gas pressure
readings (illustrated in panels C-F of Figs. 7 and 8)
were found to be even more precise. Discrepancies between calculated and measured stroke volumes averaged
0.02 ± 0.05 ml, a
difference of <1% over a range of 0.42-3.93 ml. Stroke length
estimates, based on stroke volume calculations and bellows effective
area and compliance, differed from measured values by
0.01 ± 0.66 mm, with the average reading exceeding the true distance by 2.8%. Similarly, mean stroke velocity, derived from these stroke length measurements plus estimated contraction time, deviated only slightly from actual values, differing by
0.85 ± 3.19 mm/s over a span of 8.4-60.1 mm/s. Perhaps the most important performance
parameter, stroke work output, was calculated as the product of stroke
volume and pressure generation. Calculated values ranged from 6.0 to 332.9 mJ, with the average reading being 0.5% less than that
determined by direct measurement. Absolute differences averaged
1.7 ± 5.6 mJ.
The amount of mechanical energy transmitted by the MEC3 was strongly
influenced by both stroke length and afterload conditions (Fig.
9). Stroke work outputs of 324-344
mJ were realized against pressure loads of 150-200 kPa at full
piston compression. Peak energy transfer was achieved with actuation
forces of 65-80 N peak (45-55 N mean) applied over a period
of 0.25 s. Under these conditions, total input energy needed to
actuate the device was measured at 521-796 mJ per pump cycle. This
"contractile work" was converted into hydraulic power with an
efficiency of 87 ± 3%. Of this, just over one-half (53 ± 3%) was transmitted to the accumulator, with the remainder being
stored as potential energy within the metal bellows seal. Hydraulic
conversion efficiencies were found to be independent of stroke length
and afterload pressures.

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 9.
Plot of MEC3 stroke work vs. stroke length and pressure
load. Energy transmission levels in excess of 340 mJ per actuation
cycle were achieved under peak loading conditions.
|
|
 |
DISCUSSION |
The principal aim of this study was to evaluate the prospect
of using radiotelemetry as a noninvasive means to monitor functional parameters of muscle-powered implants in conscious, untethered animals.
This test scheme was developed to allow on-demand assessment of muscle
and device performance over extended implant periods (3-24 mo)
without the need for percutaneous access lines or the administration of
tranquilizing drugs. Its ultimate purpose is to simulate, to
the degree possible, the clinical conditions under which these devices
will operate to better predict implant performance before human trials.
To this end, the SMART system was designed and its function
assessed in vitro. Two channels of telemetered pressure data
(gas and fluid) were collected and used to calculate six indexes of device function. Calculated parameters were then compared with measured
values to determine their accuracy. Estimates of peak force based on
fluid pressure readings were found to consistently underestimate actual
values by ~11%. This small, invariable error is thought to be due to
low-level shear loads supported by the piston bearing and thus not
detectable by pressure measurement. This discrepancy can be offset,
however, by simply adding a 5-N correction constant to the force
equation, effectively reducing mean calculation errors to 0.02 ± 3.2 N. All other calculated parameters fell within 3% of measured
values, with stroke volume and work output estimates proving most
accurate (mean errors <1%). These data confirm that important MEC
performance parameters can be accurately derived from telemetered
pressure readings alone, without the need to physically manipulate the
system under study.
This remote monitoring scheme could potentially be used to facilitate a
variety of studies involving the transduction of muscle power into
hydraulic energy, whether for circulatory support purposes or other
applications (e.g., actuation of artificial limbs). In addition to
aiding development of other in situ muscle energy transformers
(10), the SMART system may similarly prove beneficial to
myoplasty researchers studying the long-term effects of loading conditions on skeletal muscle ventricle performance (6, 7, 15). Moreover, this telemetric loading system could also be employed to examine functional changes brought about by various electrical training protocols, including those enhanced via drug infusion (4, 7, 9), myoblast transfer, or gene therapy. The ability to study muscle mechanics in conscious, unstressed animals
could thereby significantly improve our understanding of skeletal
muscle plasticity and help determine the feasibility of motor
prostheses powered by electrically stimulated skeletal muscle.
The next phase of MEC development, made possible by validation of the
telemetric monitoring technique detailed here, will involve use of the
SMART system to assess device function in vivo. Implant studies of
extended duration will be required to examine a number of biological
factors that may impact long-term MEC operation, including muscle
function, tendon and chest wall attachment stability, and chronic
tissue reactions. By providing a quick and simple means to access
device functional status, postimplant problems will be more rapidly
identified and the time course of performance degradation documented
before explantation. Thus causes of system failure will be quickly and
accurately diagnosed, leading to more effective design modifications
and more efficient animal use.
In the absence of mechanical difficulties, the SMART system will be
used to chart MEC and muscle function for up to 2 yr, documenting the
feasibility of operating an internal reciprocating pump powered by
muscle contractions over an indefinite period of time.
Information regarding optimum patterns of muscle activation and peak
sustainable power production will also be obtained by periodically
altering loading conditions and muscle stimulation regimens. This novel
monitoring technique may thus yield important information regarding
tissue encapsulation of long-term kinetic implants, the steady-state
work capacity of electrically trained skeletal muscle, and the degree
to which in situ skeletal muscle can be used to support the failing heart.
Conclusion.
In summary, this report details development of a third-generation MEC
and implantable test system designed to provide a practical means to
regulate pressure loads and monitor MEC function via remote
sensing. Bench studies confirm that key device parameters can be
calculated with high precision by using pressure readings received via
radiotelemetry from an implantable transmitter. This innovative
approach to chronic implant testing will allow muscle-powered motor
prostheses to be closely monitored for extended periods in conscious,
untethered animals, yielding performance data unadulterated by
tranquilizing drugs or adrenergic reactions. Implementation of this
experimental technique represents an essential step toward determining
the feasibility of harnessing muscle power for cardiac-assist purposes.
 |
ACKNOWLEDGEMENTS |
This work was supported by National Heart, Lung, and Blood
Institute Grant 1 R01 HL-59896-01A1.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: D. R. Trumble, Allegheny-Singer Research Institute, 9th Floor-South Tower,
320 East North Ave. Pittsburgh, PA 15212-4772 (E-mail: trumble{at}wpahs.org).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 18 September 2000; accepted in final form 27 November 2000.
 |
REFERENCES |
1.
Acker, MA,
Hammond RL,
Mannion JD,
Salmons S,
and
Stephenson LW.
An autologous biologic pump motor.
J Thorac Cardiovasc Surg
92:
733-746,
1986[Abstract].
2.
Acker, MA,
Hammond RL,
Mannion JD,
Salmons S,
and
Stephenson LW.
Skeletal muscle as the potential power source for a cardiovascular pump: assessment in vivo.
Science
236:
324-327,
1987[Abstract/Free Full Text].
3.
Bland, JM,
and
Altman DG.
Statistical methods for assessing agreement between two methods of clinical measurement.
Lancet
1:
307-310,
1986[Web of Science][Medline].
4.
Fritzsche, D,
Krakor R,
Asmussen G,
Widera R,
Caffier P,
Berkei J,
and
Cesla M.
Anabolic steroids (metenolone) improve muscle performance and hemodynamic characteristics in cardiomyoplasty.
Ann Thor Surg
59:
961-970,
1995[Abstract/Free Full Text].
5.
Gillum, RF.
Epidemiology of heart failure in the United States.
Am Heart J
126:
1042-1047,
1993[Web of Science][Medline].
6.
Guldner, NW,
Eichstaedt HC,
Klapproth P,
Tilmans MHI,
Thuaudet S,
Umbrain V,
Ruck K,
Wyffels E,
Bruyland M,
Sigmund M,
Messmer BJ,
and
Bardos P.
Dynamic training of skeletal muscle ventricles. A method to increase muscular power for cardiac assistance.
Circulation
89:
1032-1040,
1994[Abstract/Free Full Text].
7.
Guldner, NW,
Klapproth P,
Grosserr M,
Stephan M,
Rumpel E,
Noel R,
and
Sievers H.
Clenbuterol-supported dynamic training of skeletal muscle ventricles against systemic load. A key for powerful circulatory assist?
Circulation
101:
2213-2219,
2000[Abstract/Free Full Text].
8.
Melvin, DB,
Glos DL,
Abiog MC,
and
Litsky AS.
Coupling of skeletal muscle to a prosthesis for circulatory support.
ASAIO J
43:
M434-M441,
1997[Web of Science][Medline].
9.
Petrou, M,
Clarke S,
Morrison K,
Bowles C,
Dunn M,
and
Yacoub M.
Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardiac assist.
Circulation
99:
713-720,
1999[Abstract/Free Full Text].
10.
Reichenbach, SH,
Gustafson KJ,
Egrie GD,
Weidman JR,
Farrar DJ,
and
Hill JD.
Evaluation of a skeletal muscle energy converter in a chronic animal model.
ASAIO J
46:
482-485,
2000[Web of Science][Medline].
11.
Stewart, S,
Liang I,
Flack J,
and
Clark R.
A comprehensive cardiovascular waveform analysis program for IBM-compatible personal computers.
Biomed Instrum Technol
26:
39-47,
1992[Medline].
12.
Trumble, DR,
LaFramboise WA,
Duan C,
and
Magovern JA.
Functional properties of conditioned skeletal muscle: implications for muscle-powered cardiac assist.
Am J Physiol Cell Physiol
273:
C588-C597,
1997[Abstract/Free Full Text].
13.
Trumble, DR,
and
Magovern JA.
A permanent prosthesis for converting in situ muscle contractions into hydraulic power for cardiac assist.
J Appl Physiol
82:
1704-1711,
1997[Abstract/Free Full Text].
14.
Trumble, DR,
and
Magovern JA.
A muscle-powered energy delivery system and means for chronic in vivo testing.
J Appl Physiol
86:
2106-2114,
1999[Abstract/Free Full Text].
15.
Whalen, RL,
Richards CL,
Lim GW,
Sherman CW,
Norman JC,
Bearnson GB,
Burns GL,
and
Olsen DB.
A ventricular assist device powered by conditioned skeletal muscle.
Ann Thor Surg
68:
780-784,
1999[Abstract/Free Full Text].
J APPL PHYSIOL 90(5):1977-1985
8750-7587/01 $5.00
Copyright © 2001 the American Physiological Society